The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

RECEIVED MILESTONE PAYMENT FROM NOVO NORDISK FOR EXCLUSIVE LICENSE AGREEMENT OF UBT251

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

Reference is made to the Company's announcement dated 24 March 2025 (the "Announcement") in relation to the Exclusive License Agreement with Novo Nordisk for UBT251, a triple agonist of the receptors of GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon in clinical study for the treatment of obesity, type 2 diabetes and other diseases. Unless otherwise defined in this announcement, capitalised terms used herein shall have the same meaning as those defined in the Announcement.

The Board is pleased to announce that, on 15 July 2026, United Biotechnology (聯邦生物科技(珠海橫琴)有限公司) received a milestone payment of US$13.5 million (after deduction of Danish withholding tax) from Novo Nordisk for a global Phase II clinical trial of UBT251 Injection of overweight or obesity indication.

Under the Exclusive License Agreement and subject to the terms and conditions thereof, United Biotechnology is eligible to receive potential milestone payments of up to US$1.8 billion subject to the achievement of certain development and sales milestones, plus tiered royalties based on annual net sales in the Territory.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 16 July 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.